Drug
Dolcanatide clinical trials
Also written SP-333.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 1
Bausch Health Americas, Inc. (2) · National Cancer Institute (NCI) (1)
Studies
Open first, then newest update. How each study uses dolcanatide is read from its arms, and is right about nine times in ten.
Testing it · 3
- Dolcanatide in Preventing Colorectal Cancer in Healthy VolunteersCompletedPhase 1National Cancer Institute (NCI)NCT03300570Written as Dolcanatide
- Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)CompletedPhase 2Bausch Health Americas, Inc.NCT01983306Written as SP-333 1 mg
- Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of SP-333 Tablets in Healthy Adult SubjectsCompletedPhase 1Bausch Health Americas, Inc.NCT01705938Written as SP-333
Codes
What other systems call dolcanatide · ClinicalTrials.gg INT000602
- MeSH (NLM) C000614048dolcanatideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) WU977T914KDOLCANATIDEConfirmed FDA, NLM
- NCI Thesaurus C153478DolcanatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000614048 | dolcanatide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | WU977T914K | DOLCANATIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C153478 | Dolcanatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.